Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Long-Term Survival of Advanced Breast Cancer with Letrozole and Palbociclib: Can the Intent Change from Palliation to Cure?

  • 4 Accesses

Abstract

We report a patient with advanced hormone-positive, HER2-negative breast cancer with contralateral supraclavicular node and subpleural lung nodules who was treated with letrozole and palbociclib with palliative intent. After 2 years of treatment, PET–CT showed disease confined only to the breast and she underwent modified radical mastectomy. Histopathology showed a 1-mm focus of invasive carcinoma. She was continued on letrozole and palbociclib and has completed 3 years since the diagnosis of metastatic disease and is in complete remission.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Rastogi S, Gulia S, Bajpai J, Ghosh J, Gupta S. Oligometastatic breast cancer: a mini review. Indian J Med Paediatr Oncol Off J Indian Soc Med Paediatr Oncol. 2014;35:203–6.

  2. 2.

    Badwe R, et al. Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial. Lancet Oncol. 2015;16:1380–8.

  3. 3.

    Soran A, et al. Randomized trial comparing resection of primary tumor with no surgery in stage IV breast cancer at presentation: protocol MF07-01. Ann Surg Oncol. 2018;25:3141–9.

  4. 4.

    Thomas A, Khan SA, Chrischilles EA, Schroeder MC. Initial surgery and survival in stage IV breast cancer in the United States, 1988–2011. JAMA Surg. 2016;151:424–31.

  5. 5.

    Xie Y, et al. Surgery of the primary tumor improves survival in women with stage IV breast cancer in Southwest China: a retrospective analysis. Medicine (Baltimore). 2017;96:e7048.

  6. 6.

    Milano MT, et al. Oligometastatic breast cancer treated with hypofractionated stereotactic radiotherapy: some patients survive longer than a decade. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2019;131:45–51.

  7. 7.

    Trovo M, et al. Radical radiation therapy for oligometastatic breast cancer: results of a prospective phase II trial. Radiother Oncol. 2018;126:177–80.

  8. 8.

    Rugo HS, et al. Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. Breast Cancer Res Treat. 2019;174:719–29.

  9. 9.

    Diéras V, et al. Palbociclib with letrozole in postmenopausal women with ER+/HER2− advanced breast cancer: hematologic safety analysis of the randomized PALOMA‐2 trial. Oncologist. 2019;24:1514–25. https://doi.org/10.1634/theoncologist.2019-0019.

Download references

Funding

Not applicable.

Author information

Correspondence to Manikandan Dhanushkodi.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Informed Consent

Informed consent was obtained.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Dhanushkodi, M., Velusamy, S. Long-Term Survival of Advanced Breast Cancer with Letrozole and Palbociclib: Can the Intent Change from Palliation to Cure?. Indian J Gynecol Oncolog 18, 28 (2020). https://doi.org/10.1007/s40944-020-0376-0

Download citation

Keywords

  • Advanced breast cancer
  • Letrozole and palbociclib
  • Long-term survival